Dasatinib and Quercetin as Senolytic May Cause Brain Damage

Key Takeaways

• D+Q induces oligodendrocyte dysfunction and demyelination in aged mice
• Dosing matches regimens used in human senolytic trials
• No overt oligodendrocyte death despite white‑matter injury
• Findings urge caution for D+Q clinical use and anti‑aging claims

Pulse Analysis

Senolytics have attracted attention as a way to clear senescent cells and extend healthspan, with dasatinib and quercetin (D+Q) emerging as the most studied pair. Early mouse studies reported modest lifespan extensions, prompting multiple phase I/II trials in older adults and patients with age‑related diseases. The appeal lies in the compounds’ existing FDA approval for leukemia (dasatinib) and their over‑the‑counter availability (quercetin), creating a perception of low‑risk, high‑reward therapy for aging.

The new PNAS paper disrupts that narrative by demonstrating that intermittent D+Q dosing—5 mg/kg dasatinib and 50 mg/kg quercetin, identical to protocols linked to survival benefits—produces pronounced demyelination in the corpus callosum of 22‑month‑old mice. Researchers observed oligodendrocyte stress, activation of the unfolded protein response, and white‑matter loss without massive cell death, indicating a subtle but damaging functional impairment. Because the dosage mirrors that used in human trials, the findings suggest a plausible translational risk: chronic senolytic exposure could compromise myelin integrity, potentially manifesting as cognitive decline or motor deficits in patients.

The broader implication is a call for rigorous neuro‑safety endpoints in ongoing D+Q studies and a reevaluation of the supplement market’s hype around anti‑aging pills. Alternatives such as senomorphics, lifestyle‑based inflammation reduction, or compounds like fisetin—though not proven senolytic in humans—may offer safer routes. Regulators and investigators must balance the promise of senescent‑cell clearance against unintended neurotoxicity, ensuring that any longevity intervention does not trade one age‑related disease for another.